Clinical Trial: S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: S0309, Myeloma Specimen Repository Protocol, Ancillary

Brief Summary:

RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors find better ways to ways to treat the cancer.

PURPOSE: The purpose of this study is to collect and store blood and bone marrow samples from patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia, amyloidosis, and monoclonal gammopathy of undetermined significance to be tested in the laboratory.


Detailed Summary:

OBJECTIVES:

  • Maintain and expand tissue repositories of myeloma specimens from uniformly treated Southwest Oncology Group (SWOG) patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia, amyloidosis, or monoclonal gammopathy of undetermined significance.
  • Utilize scientific information generated from intergroup and collaborative studies to assist the SWOG Myeloma Committee in the development of new and more effective treatment regimens for these patients.

OUTLINE: Patients receive treatment as directed by the treatment protocols on which they are registered. Specimens of blood and/or marrow are submitted to the Myeloma Repository. The status of the patient (e.g., pre-study, post-remission, or relapse) will be recorded prior to specimen collection.

PROJECTED ACCRUAL: Not specified


Sponsor: Southwest Oncology Group

Current Primary Outcome:

  • Maintenance and expansion of tissue repositories of myeloma specimens from uniformly treated SWOG patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia, amyloidosis, or monoclonal gammopathy of undetermined significance [ Time Frame: 7 years ]
  • Development of new and more effective treatment regimens for these patients using scientific information generated from intergroup and collaborative studies [ Time Frame: 7 years ]


Original Primary Outcome:

  • Maintainence and expansion of tissue repositories of myeloma specimens from uniformly treated SWOG patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinema, amyloidosis, or monoclonal gammopathy of undetermined significance
  • Development of new and more effective treatment regimens for these patients using scientific information generated from intergroup and collaborative studies


Current Secondary Outcome:

Original Secondary Outcome:

Information By: Southwest Oncology Group

Dates:
Date Received: June 11, 2009
Date Started: November 2003
Date Completion:
Last Updated: April 1, 2015
Last Verified: April 2015